

ANNUAL IMPACT REPORT

Our 2023 results



Dutch network for cardiovascular research, 50+ sites




MESSAGE FROM OUR CHAIRMAN


“In 2023, we excelled by successfully advancing our strategy and achieving record recruitment across industry and investigator initiated projects. Grateful for fruitful collaborations with academic and pharmaceutical partners, we look forward to continuing our mission for effective contributions to healthcare innovation for cardiovascular patients in 2024.”

Dr Martin E.W. Hemels FEHRA FESC, cardiologist

STUDY PORTFOLIO



ENROLLMENT



OUR CONTRIBUTIONS TO INDUSTRY INITIATED TRIALS

- We proudly expanded collaborations and have successfully brought in 16 new studies.
- Citeline's [2023 European Benchmark](#) shows that research networks like WCN are key drivers in the Netherlands' strong position as a clinical trials ecosystem.
- European guidelines for the treatment of several cardiac conditions were updated based on the results of trials, to which members of the WCN network made significant contributions.
- Our focus on early clinical development has effectively expanded our study portfolio, with an increased number of early-phase (I-II) projects.
- Our metrics-driven approach continues to support our contributions and successes.



OUR CONTRIBUTIONS TO INVESTIGATOR INITIATED STUDIES



- WCN congratulates the team of our drug repurposing trial, [LoDoCo2](#), on new publications and its second PhD graduate.
- Our site members successfully completed recruitment in [DECISION](#) (UMCG), [CLEAR Synergy](#) (PHRI), and [ARTESiA](#) (PHRI) of our academic partners.
- Our DUTCH-WAIST trial is ready to start, focusing on obesity as the driver of atrial fibrillation.

UPDATES FROM OUR ORGANIZATION

- The [European Clinical Trial Regulation](#) has been further embraced by our site members, resulting in reduced cycle times and accelerated First Patient In timelines.
- Ongoing contributions to [DCRE](#) and [FAST](#), along with collaborations with ZonMw and the VWS ministry, strengthen our efforts to enhance the Dutch clinical trial ecosystem, providing a fit-for-purpose system for both innovative and repurposed drugs.
- Receiving the go-ahead from our Advisory Board for their transition into a Supervisory Board marks the completion of the professionalization of our organization's governance.

